Inhibition of prostate carcinogenesis by combined active immunoprophylaxis

Carla De Giovanni, Stefania Croci, Giordano Nicoletti, Lorena Landuzzi, Arianna Palladini, Tania Pannellini, Ludovica Borgia, Manuela Iezzi, Emma Di Carlo, Anna Maria Orengo, Ronald C. Kennedy, Pier Luigi Lollini, Patrizia Nanni, Piero Musiani

Research output: Contribution to journalArticlepeer-review


The aim of this study is to investigate whether an active immunoprophylactic approach combining specific antigens and adjuvant stimuli would be able to inhibit prostate carcinogenesis in transgenic TRAMP mice. A vaccine consisting of allogeneic large T antigen (TAg)-positive SV40-transformed cells combined with systemic recombinant IL-12 was administered to TRAMP mice, starting from when they were still tumor-free at 5-6 weeks of age. The combined vaccine significantly inhibited prostate carcinogenesis, giving a more than doubled median latency time of prostatic tumors (53 weeks in comparison to 26 weeks in control mice). Vaccination with cells alone or IL-12 treatment alone was poorly effective (median latency of 30 and 39 weeks, respectively). The combined vaccine induced a very high CD4 response biased toward the Th1 pathway, with the induction of a humoral response that included TAg-specific antibodies. Therefore, such active immunoprophylactic approach based on the combination of allogeneic SV40 TAg-positive cells and systemic administration of recombinant IL-12 significantly delayed autochthonous urogenital carcinogenesis driven by SV40 TAg in TRAMP mice.

Original languageEnglish
Pages (from-to)88-94
Number of pages7
JournalInternational Journal of Cancer
Issue number1
Publication statusPublished - Jul 1 2007


  • Cell vaccine
  • IL-12
  • Prostate cancer
  • TRAMP mice

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Inhibition of prostate carcinogenesis by combined active immunoprophylaxis'. Together they form a unique fingerprint.

Cite this